Title Earning Preview: Option Care Health Inc revenue this quarter expected to increase by 13.24%, and institutional views are bullish Abstract Option Care Health Inc is scheduled to report quarterly results on February 24, 2026 Pre-Market, with investors watching for revenue, margins, and adjusted EPS against a backdrop of double-digit top-line growth expectations and supportive recent analyst ratings. Market Forecast Consensus compiled ahead of the release points to Option Care Health Inc delivering revenue of 1.46 billion in the upcoming quarter, implying year-over-year growth of 13.24%, alongside an adjusted EPS estimate of 0.46, up 36.36% year over year, and an EBIT projection of 98.99 million, up 6.72% year over year. There is no explicit market forecast for gross profit margin or net profit margin in the current dataset, so margin expectations are being inferred from volume growth and operating leverage rather than guided figures. The core revenue engine remains the company’s payer-channel mix, with commercial and government books expected to carry the growth load as therapy volumes and mix trends sustain the company’s double-digit top-line trajectory. Within that, the commercial channel, which contributed 1.25 billion last quarter, is positioned to be the primary growth contributor as the company targets an approximate 13.24% year-over-year increase in total revenue for the to-be-reported quarter. Last Quarter Review Option Care Health Inc’s previous quarter delivered revenue of 1.44 billion (up 12.24% year over year), a gross profit margin of 19.02%, GAAP net profit attributable to shareholders of 51.82 million, a net profit margin of 3.61%, and adjusted EPS of 0.45 (up 45.16% year over year). A notable financial highlight was broad-based outperformance versus consensus markers: revenue exceeded projections by 22.26 million, EBIT reached 108.37 million versus a lower estimate, and adjusted EPS topped expectations by 0.02; sequentially, net profit rose by 2.56%. The main business composition underscored a payer-driven mix—commercial contributed 1.25 billion, government contributed 172.75 million, and patient/self-pay contributed 10.08 million—reinforcing that the commercial book remains the foundational revenue base, while overall company revenue growth ran at 12.24% year over year. Current Quarter Outlook

Commercial and government payer mix: sustaining revenue growth and navigating margin quality

The company’s expected revenue trajectory for the upcoming quarter—1.46 billion, or 13.24% year-over-year growth—places the spotlight on its commercial and government payer channels. The commercial channel, which generated 1.25 billion in the previous quarter, provides the scale and patient throughput that anchor top-line visibility. In the near term, growth levers appear to be volume expansion in core therapies and steady referral flows, supporting the forecasted step-up in revenue even without explicit margin guidance. Management’s prior quarter delivery of a 19.02% gross margin and a 3.61% net margin sets a reference point, but investors will monitor whether the anticipated revenue growth converts into incremental gross profit at a healthy rate, as drug acquisition costs and therapy-mix effects can moderate gross margin even when volumes are rising. The earnings construct for this quarter is consistent with positive operating leverage: a 36.36% year-over-year increase in adjusted EPS to 0.46 outpaces the 13.24% revenue growth assumption. That spread implies productivity improvements and expense discipline, supporting margins despite potential mix headwinds. EBIT is forecast at 98.99 million with 6.72% year-over-year growth; this more modest EBIT growth versus EPS signals a likely benefit from below-the-line items and share count effects, while also suggesting that the company is emphasizing efficiency and SG&A control to protect profitability. Investors will weigh this against the previous quarter’s 108.37 million EBIT, evaluating whether any assumed seasonal patterns, timing effects, or mix shifts explain the sequential step-down implied by forecasts. Beyond the headline numbers, the payer mix itself can influence realized margins. A higher tilt toward commercial payers typically offers better unit economics than government reimbursement, which can help sustain gross profit margin near or modestly above the 19.02% prior-quarter level if volumes skew favorably. Conversely, if growth disproportionately comes from categories with lower reimbursement or higher pass-through drug content, gross margin may stay stable rather than expand, making operating leverage below the line—through SG&A efficiency and interest expense management—more crucial for delivering the 0.46 EPS target.

Commercial channel as the primary growth lever: scale advantages and execution priorities

The commercial channel’s 1.25 billion contribution last quarter underscores its importance as a growth engine and a key determinant of earnings quality. When commercial volumes expand, each incremental dollar of revenue tends to carry better gross profit characteristics than government-funded services, providing the backbone for EPS acceleration. The company’s forecasted 13.24% revenue growth paired with 36.36% EPS growth suggests a positive mix and cost trajectory that is likely to be anchored in the commercial book in the near term. Investors will watch whether this growth is broad-based across therapies and sites or concentrated in a narrower set of high-volume services, as the breadth of contribution often influences both sustainability and volatility of margins. Operational execution within the commercial channel is central this quarter: maintaining clean claims, optimizing reimbursement cycles, and sustaining referral relationships help translate volume into cash conversion. Given the prior quarter’s robust outperformance on EBIT and EPS, the bar for execution remains high, and any slippage in cycle-time or collections could pressure EBIT, which is already forecast to grow more slowly than EPS year over year. With 172.75 million of revenue tied to government sources last quarter and only 10.08 million from patient/self-pay, incremental commercial growth should continue to dominate absolute top-line expansion, reinforcing overall revenue momentum even if per-unit economics show typical quarterly variability. Pricing and contract terms across commercial payers can also influence quarter-to-quarter profitability. As the company scales, it typically benefits from procurement leverage and process efficiencies across its network. That can help offset any temporary margin softness stemming from therapy or drug mix while still supporting the EPS step-up expected this quarter. Investors will likely parse commentary around volume growth, case mix, and reimbursement trends to validate the durability of the commercial engine as the central driver of both revenue and earnings.

Price-moving variables this quarter: margin durability, operating leverage, and expectations risk

Three factors appear most likely to drive the stock’s reaction around results: gross margin durability versus volume-driven growth, the degree of operating leverage in SG&A, and the gap between consensus assumptions and delivered metrics. If gross margin holds near the 19.02% reference level while revenue reaches the anticipated 1.46 billion, EBIT conversion will hinge on how much incremental cost is required to support that growth. The 98.99 million EBIT forecast implies a more measured year-over-year rise than EPS, so commentary on expense timing, staffing, and process efficiency will be central to the narrative. In particular, a scenario where revenue meets expectations but EBIT trends lighter than the prior quarter could still be perceived constructively if EPS reaches 0.46 with evidence of sustainable cost control and cash generation. On the other hand, any shortfall on revenue versus the 13.24% implied growth could compress sentiment, especially if accompanied by steady or lower gross margins. Because the previous quarter beat both revenue and EPS expectations, investor positioning may assume repeatable outperformance; this raises the bar for positive surprise. The absence of explicit margin guidance in the forecast set places greater emphasis on qualitative remarks about therapy mix and payer dynamics. A clear articulation of how mix is evolving and how procurement and process efficiencies offset margin pressure would likely be a key support for the share price. Finally, sequential context matters. The previous quarter posted 108.37 million of EBIT and a 0.45 EPS print, and net profit grew 2.56% quarter on quarter; the current period’s projected 98.99 million EBIT and 0.46 EPS imply a more EPS-focused progression. If management demonstrates that this reflects normal seasonality or deliberate optimization of the cost base, the market may accept the EBIT cadence as a trade-off for stronger per-share profitability. Conversely, if the earnings path appears reliant on below-the-line factors without sustainable operating improvements, investors could discount the durability of EPS growth, making the revenue and gross margin prints decisive for the stock’s immediate move. Analyst Opinions Across the views gathered in the specified period, the skew is decisively positive: 100% of the collected opinions are bullish and 0% are bearish. Two well-followed institutions expressed constructive stances. One firm maintained an Outperform rating while raising the price target to 42.00, and another reiterated a Buy rating, lifting its price target to 40.00. Independently compiled summaries during January indicated a Buy average rating and mean price targets in the mid-to-high 30s, suggesting a supportive, albeit not euphoric, positioning backdrop. The bullish case cited by these institutions aligns with the quantitative setup detailed above: consensus anticipates 13.24% year-over-year revenue growth and a 36.36% uplift in adjusted EPS to 0.46 for the upcoming quarter. Analysts point to consistent delivery against expectations, as evidenced by last quarter’s revenue and EPS beats, and to an execution framework that has supported both scale and efficiency. The outlook for the next print emphasizes the company’s ability to translate volume into profit while maintaining disciplined spending, and the raised price targets reflect increased confidence in this earnings trajectory rather than a multiple expansion thesis alone. There is also a recognition among bullish analysts that the company’s payer mix and scale can provide resilience when margins fluctuate with therapy mix or drug pass-through dynamics. In this view, the forecasted step-up in EPS relative to revenue implies that the company is managing its expense base efficiently and capturing incremental profitability as volumes rise. With last quarter’s GAAP net margin at 3.61% and gross margin at 19.02%, analysts see room for per-share earnings to improve even if gross margin stays broadly stable, provided operating leverage holds. Investors should note the balance of expectations implicit in the new targets. A 40.00 to 42.00 price target corridor suggests that the market is looking for continued double-digit revenue growth, steady cash generation, and consistent execution in the commercial channel. The previous quarter’s EBIT outperformance and EPS beat build credibility, but they also heighten the threshold for a positive surprise. In the near term, analysts indicate that delivering on the 1.46 billion revenue mark and near-0.46 EPS—accompanied by a stable gross margin profile and clear commentary on payer mix—would likely validate the constructive stance. In summary, the predominant institutional view is that Option Care Health Inc remains on track to post another quarter of healthy top-line growth and disproportionate EPS expansion, supported by scale advantages and disciplined cost management. The earnings day debate is likely to revolve around the quality of margins relative to volume growth, the consistency of the commercial channel’s contribution, and the sustainability of operating leverage. As long as results align with the indicated revenue and EPS markers, the collected analyst opinions suggest the shares are positioned to be rewarded for confirmation of the trend rather than solely for a large surprise.